Mots-Clés

Bioinformatics cancer genomics pediatric brain tumors single-cell genomics, transcriptomics, epigenetics treatment resistance

Description

Institut Curie Research Center

Institut Curie is a major player in the research and fight against cancer. It consists of a Hospital group and a Research Center of more than 1000 employees with a strong international representativeness.

The objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.

Laboratory

The Cavalli Lab is seeking a highly motivated scientist interested in deciphering pediatric brain treatment resistance 

The Cavalli Lab is part of the "Bioinformatics and Computational Systems Biology of Cancer" Unit (U900 INSERM, Mines ParisTech, Institut Curie) at Institut Curie, which consists of ~90 researchers and students. It is a very active and growing interdisciplinary team of bioinformaticians, biologists, physicians, mathematicians, statisticians, physicists, and computer scientists (U900 Unit page).

The Cavalli Lab, investigates tumor heterogeneity, targeting clinically relevant questions. The goal of our genomic approaches is to explore clinically relevant aspects of brain tumor biology. We pursue this goal using patient samples profiling, investigating temporal and intra-tumoral/spatial heterogeneity as well as tumor/tumor microenvironment interactions in adult gliomas and pediatric brain tumors. Projects in the Cavalli lab are developed within a dynamic and collaborative environment with other researchers and clinicians at Institut Curie and beyond.

The project

We seek a highly motivated and talented individual to be part of the ENCOURAGER project, a collaborative effort funded by Fight Kids Cancer. This project focuses on studying the causes of resistance to targeted therapy in pediatric gliomas. The applicant will investigate the longitudinal evolution of gliomas under treatment with the analysis of multi-omic profiling of pediatric glioma PDX models at single-cell resolution. This project is in close collaboration with Dr. Ana Guerreiro Stücklin lab at University Children’s Hospital Zurich performing the experiments on the tumor samples and PDX models. The successful candidate should hold a recent PhD, have a track record of creativity in developing analytic strategies. He/she has the ambition to tackle the complexity of tumor biology and intra-tumoral heterogeneity using computational analysis of cutting-edge sequencing datasets.

Responsibilities

• Drive and develop a scientific project focused on tumor heterogeneity/treatment resistance
• Perform end-to-end data analysis: QC, processing, results, visualization, interpretation…
• Analyze single-cell RNA-seq and single-nucleus ChIP-seq datasets
• Perform high dimensional data analysis and integrative ‘omic’ data analysis
• Use and develop methods and strategies to investigate treatment resistance mechanism

Training and Skills required

• PhD in bioinformatics, statistics or computer science with knowledge and interest in biology
• Have a track record of creativity in developing analytic strategies
• Strong foundation of knowledge in one or more of the following: genomics, cancer biology, statistics
• Have evidence of scientific accomplishment via peer-reviewed publications
• Excellent computational skills
• Experience working in a Unix environment
• Experience in statistical analysis using R
• Experience with high-throughput sequencing data analysis
• Experience with single-cell RNA-seq analysis is desirable

• Proficiency in English and excellent scientific writing skills
• Understanding of cancer cell biology is an asset as well as experience of collaboration with biologists for solving concrete biological problems

Abilities

• Must be self-motivated, capable to work in autonomy
• Have a good team spirit
• Ability to communicate with clinicians and biologists

Benefits: Collective catering and 70% reimbursement of annual travel costs, company health insurance scheme